Core Viewpoint - The company, Gilead Sciences-B (01672), has seen its stock price increase by over 10% following the announcement of a share buyback program, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - Gilead Sciences announced its intention to repurchase shares based on the general authorization granted by shareholders at the annual general meeting held on May 22 this year [1] - The company is authorized to buy back up to 96.2846 million shares, which represents 10% of the total issued shares (excluding treasury shares) as of the date of the annual general meeting [1] - The board has decided to exercise the buyback authorization and will repurchase shares in the open market as market conditions permit, using up to HKD 300 million from internal financial resources [1] Group 2: Confidence in Business Prospects - The board believes that the proposed share buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The buyback is expected to benefit the company and align with the overall best interests of the company and its shareholders [1]
歌礼制药-B涨超10% 拟斥最多3亿港元回购股份